These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
766 related articles for article (PubMed ID: 20731472)
1. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Taiwo B; Murphy RL; Katlama C Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472 [TBL] [Abstract][Full Text] [Related]
2. Darunavir: a review of its use in the management of HIV infection in adults. McKeage K; Perry CM; Keam SJ Drugs; 2009; 69(4):477-503. PubMed ID: 19323590 [TBL] [Abstract][Full Text] [Related]
4. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors. Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706 [TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Cvetkovic RS; Goa KL Drugs; 2003; 63(8):769-802. PubMed ID: 12662125 [TBL] [Abstract][Full Text] [Related]
6. Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. Boyd MA; Hill AM Pharmacoeconomics; 2010; 28 Suppl 1():17-34. PubMed ID: 21182341 [TBL] [Abstract][Full Text] [Related]
7. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC; Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787 [TBL] [Abstract][Full Text] [Related]
8. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. ; Boyd MA; Kumarasamy N; Moore CL; Nwizu C; Losso MH; Mohapi L; Martin A; Kerr S; Sohn AH; Teppler H; Van de Steen O; Molina JM; Emery S; Cooper DA Lancet; 2013 Jun; 381(9883):2091-9. PubMed ID: 23769235 [TBL] [Abstract][Full Text] [Related]
9. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]
10. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). Ruane P; Alas B; Ryan R; Perniciaro A; Witek J AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412 [TBL] [Abstract][Full Text] [Related]
11. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL; Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077 [TBL] [Abstract][Full Text] [Related]
13. [Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Arribas JR Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427 [TBL] [Abstract][Full Text] [Related]
14. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940 [TBL] [Abstract][Full Text] [Related]
15. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI; Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797 [TBL] [Abstract][Full Text] [Related]
16. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G; Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627 [TBL] [Abstract][Full Text] [Related]